^
Association details:
| Biomarker: | PTEN deletion |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | mirdametinib (PD-0325901) (MEK inhibitor) + PF-04691502 (mTOR inhibitor, PI3K inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer
Excerpt:
Combined inhibition of PI3K/mTOR (PF-04691502) and MEK (PD-0325901) leads to regression of transplanted KrasG12D; Ptendel ovarian adenocarcinomas in vivo…Combining PF-04691502 and PD-0325901 led to a greater effect than either agent alone, with striking tumor regression (>20% volume reduction) in all 9 mice (mean volume 80.7% ± 5.0 smaller on day 7 compared with day 0 tumor volume)...
DOI:
10.1158/1535-7163.MCT-11-0240
